Fig. 4.

Low dose levetiracetam normalizes DG/CA3 activation and improves task-related memory performance on critical lure items in participants with aMCI. Top graphs show mean fMRI activity during lure trials correctly called similar. Bottom graphs show behavioral performance as the proportion of lure trials called “old”, “new” and “similar”. For each cohort all analyses were within-subject comparing placebo with drug treatment. (A) In the 62.5 mg BID cohort levetiracetam did not significantly reduce activity in the DG/CA3 in participants with aMCI although activity under drug treatment was no longer significantly different from healthy control subjects. (B) In the 62.5 mg BID cohort levetiracetam improved memory performance in aMCI participants by reducing errors in which lures were incorrectly judged “old”, with more correct judgments of “similar”. (C) In the 125 mg BID cohort levetiracetam significantly reduced activation in the DG/CA3 and (D) significantly improved memory performance. (E) In the 250 mg BID cohort treatment levetiracetam did not reduce activity in the DG/CA3 and (F) did not alter memory performance in these patients. Values are means ± SEM. *p < 0.05.